PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
=== Interactions === IRAP has been reported to interact through its cytoplasmic domain with various proteins involved in vesicular trafficking, organelle tethering, and cytoskeleton remodeling. These proteins include tankyrase-1, tankyrase-2, and p115, which regulate Golgi vesicle trafficking; vimentin, an intermediate cytoskeleton filament; and the actin remodeling protein FHOS. Furthermore, IRAP was found to associate with AS160/Tbc1d4, a Rab GTPase activating protein (GAP) specific for Rab8, 10, and 14. This suggests that IRAP plays a role in recruiting AS160 to endocytic membranes. Apart from its association with intracellular trafficking proteins, IRAP has also been also observed to interact with proteins present in Glut4 storage vesicles (GSVs), such as sortilin, LRP1 and Glut4 in adipocytes. Under inflammatory conditions its role in GSV trafficking in adipocytes is regulated by the TNFa protein via glycosylation. Recently, its interaction with the z chain of the TCR (T-cell receptor) and the Lck kinase in T lymphocytes was discovered. In dendritic cells, IRAP-dependent vesicle trafficking and translocation to the phagocytic cup is regulated by immune receptors, such as TLR4 and FcgRs. Finally, IRAP has been proposed to interact with major histocompatibility complexes class-I (MHC-I) in specialized endosomes in DCs. There it exhibits roles in antigen cross-presentation.
He played the opening six matches of the year, but struggled to make a significant impact, and he was dropped for the round seven match against Hawthorn at the Melbourne Cricket Ground. The same weekend, when Melksham was playing for Melbourne's VFL affiliate team, the Casey Demons, he was reported twice and subsequently received a one-match suspension. He was recalled to the senior side for the thirty-five-point win against Gold Coast at TIO Traeger Park in round ten. He played the remainder of the season in a new position as a defensive forward, and kicked twenty-one goals following his return, with Fox Sports Australia reporter, Brayden May, writing the new role had "breathed new life" into Melksham. Melksham excelled in his new role as a forward in 2018, finishing with a career-high 32 goals for the season as Melbourne made its first finals series since 2006. Highlights included a five-goal, best on ground performance, against Carlton in Round 9 and four goals against West Coast in a dramatic Round 22 win which confirmed Melbourne's position in the top 8. Despite Melbourne's drastic form slump in 2019, Melksham played consistently in the early rounds, before a foot injury in Round 8 against Gold Coast sidelined him for three months. He returned to form in 2020, playing every match of the shortened season, including captaining the side to victory against North Melbourne in Round 11, due to the absence of Max Gawn and Jack Viney.
Minoxidil causes a redistribution of cellular iron through its apparent capacity to bind this metal ion. By binding iron in a Fenton-reactive form, intracellular hydroxyl radical production would ensue, but hydroxyl would be immediately trapped and scavenged by the minoxidil to generate a nitroxyl radical. It is presumed that this nitroxyl radical will be capable of reduction by glutathione to reform minoxidil. Such a process would cycle until the minoxidil is otherwise metabolized and would result in rapid glutathione depletion with glutathione disulphide formation and therefore with concomitant consumption of NADPH/NADH and other reducing equivalents. Minoxidil inhibited PHD by interfering with the normal function of ascorbate, a cofactor of the enzyme, leading to a stabilization of HIF-1α protein and a subsequent activation of HIF-1. In an in vivo angiogenesis assay, millimolar minoxidil increased blood vessel formation in a VEGF-dependent manner. Minoxidil inhibition of PHD occurs via interrupting ascorbate binding to iron. The structural feature of positioning amines adjacent to nitric oxide may confer the ability of millimolar minoxidil to chelate iron, thereby inhibiting PHD. Minoxidil is capable of tetrahydrobiopterin inhibition as a cofactor for nitric oxide synthase. Minoxidil stimulates prostaglandin E2 production by activating COX-1 and prostaglandin endoperoxide synthase-1 but inhibits prostacyclin production.
Recent studies have detected the presence of significant levels of dioxins in the commercial shrimp Aristeus antennatus and significant levels of persistent organic pollutants in mesopelagic and bathypelagic cephalopods. Climate-driven processes and climate change will affect the frequency and intensity of cascading, with unknown effects on the benthic fauna. Another potential effect of climate change is related to energy transport from surface waters to the seafloor. Primary production will change in the surface layers according to sun exposure, water temperature, major stratification of water masses, and other effects, and this will affect the food chain down to the deep seafloor, which will be subject to differences in quantity, quality, and timing of organic matter input. As commercial fisheries move into deeper waters, all of these effects will affect the communities and populations of organisms in cold seeps and the deep sea in general.
Sources: en.wikipedia.org
===== MeSH D08.811.277.040 – acid anhydride hydrolases (EC 3.6) ===== MeSH D08.811.277.040.025 – adenosinetriphosphatase MeSH D08.811.277.040.025.095 – ca(2+) mg(2+)-atpase MeSH D08.811.277.040.025.125 – ca(2+)-transporting atpase MeSH D08.811.277.040.025.150 – dynein atpase MeSH D08.811.277.040.025.237 – muts dna mismatch-binding protein MeSH D08.811.277.040.025.281 – muts homolog 2 protein MeSH D08.811.277.040.025.303 – n-ethylmaleimide-sensitive proteins MeSH D08.811.277.040.025.325 – proton-translocating atpases MeSH D08.811.277.040.025.325.249 – bacterial proton-translocating atpases MeSH D08.811.277.040.025.325.500 – chloroplast proton-translocating atpases MeSH D08.811.277.040.025.325.625 – h(+)-k(+)-exchanging atpase MeSH D08.811.277.040.025.325.750 – mitochondrial proton-translocating atpases MeSH D08.811.277.040.025.325.875 – vacuolar proton-translocating atpases MeSH D08.811.277.040.025.450 – kinesin MeSH D08.811.277.040.025.525 – myosins MeSH D08.811.277.040.025.525.500 – myosin type i MeSH D08.811.277.040.025.525.750 – myosin type ii MeSH D08.811.277.040.025.525.750.124 – cardiac myosins MeSH D08.811.277.040.025.525.750.124.249 – atrial myosins MeSH D08.811.277.040.025.525.750.124.500 – ventricular myosins MeSH D08.811.277.040.025.525.750.374 – nonmuscle myosin type iia MeSH D08.811.277.040.025.525.750.500 – nonmuscle myosin type iib MeSH D08.811.277.040.025.525.750.750 – skeletal muscle myosins MeSH D08.811.277.040.025.525.750.875 – smooth muscle myosins MeSH D08.811.277.040.025.525.812 – myosin type iii MeSH D08.811.277.040.025.525.843 – myosin type iv MeSH D08.811.277.040.025.525.875 – myosin type v MeSH D08.811.277.040.025.600 – na(+)-k(+)-exchanging atpase MeSH D08.811.277.040.050 – apyrase MeSH D08.811.277.040.330 – gtp phosphohydrolases MeSH D08.811.277.040.330.200 – dynamins MeSH D08.811.277.040.330.200.100 – dynamin i MeSH D08.811.277.040.330.200.200 – dynamin ii MeSH D08.811.277.040.330.200.300 – dynamin iii MeSH D08.811.277.040.330.300 – gtp-binding proteins MeSH D08.811.277.040.330.300.100 – gtp phosphohydrolase-linked elongation factors MeSH D08.811.277.040.330.300.100.200 – peptide elongation factor g MeSH D08.811.277.040.330.300.100.700 – peptide elongation factor tu MeSH D08.811.277.040.330.300.100.800 – peptide elongation factor 1 MeSH D08.811.277.040.330.300.100.850 – peptide elongation factor 2 MeSH D08.811.277.040.330.300.200 – heterotrimeric gtp-binding proteins MeSH D08.811.277.040.330.300.200.100 – gtp-binding protein alpha subunits MeSH D08.811.277.040.330.300.200.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D08.811.277.040.330.300.200.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D08.811.277.040.330.300.200.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D08.811.277.040.330.300.200.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D08.811.277.040.330.300.200.100.400 – gtp-binding protein alpha subunits, gs MeSH D08.811.277.040.330.300.200.800 – transducin MeSH D08.811.277.040.330.300.400 – monomeric gtp-binding proteins MeSH D08.811.277.040.330.300.400.100 – adp-ribosylation factors MeSH D08.811.277.040.330.300.400.100.100 – ADP-ribosylation factor 1 MeSH D08.811.277.040.330.300.400.400 – rab gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.025 – rab1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.050 – rab2 gtp-binding protein MeSH D08.811.277.040.330.300.400.400.100 – rab3 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.100.500 – rab3a gtp-binding protein MeSH D08.811.277.040.330.300.400.400.150 – rab4 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.200 – rab5 gtp-binding proteins MeSH D08.811.277.040.330.300.400.450 – ral gtp-binding proteins MeSH D08.811.277.040.330.300.400.462 – ran gtp-binding protein MeSH D08.811.277.040.330.300.400.475 – rap gtp-binding proteins MeSH D08.811.277.040.330.300.400.475.100 – rap1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.500 – ras proteins MeSH D08.811.277.040.330.300.400.500.300 – oncogene protein p21(ras) MeSH D08.811.277.040.330.300.400.500.600 – proto-oncogene proteins p21(ras) MeSH D08.811.277.040.330.300.400.700 – rho gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.050 – cdc42 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.060 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D08.811.277.040.330.300.400.700.100 – rac gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.100.500 – rac1 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.200 – rhoa gtp-binding protein MeSH D08.811.277.040.330.300.400.700.300 – rhob gtp-binding protein MeSH D08.811.277.040.465 – nucleoside-triphosphatase MeSH D08.811.277.040.600 – pyrophosphatases MeSH D08.811.277.040.600.399 – inorganic pyrophosphatase MeSH D08.811.277.040.600.800 – thiamine pyrophosphatase MeSH D08.811.277.040.850 – thiamin-triphosphatase
=== Celeste Pacquet === Celeste Pacquet (Katrine De Candole) is a private wealth manager at Pierpoint. Yasmin meets her at a party hosted by her family friend Maxim Alonso, and Celeste plays along with Yasmin's assumption that she is a sex worker before eventually revealing her actual job. Yasmin, growing disgruntled with the FX desk, becomes increasingly drawn to working for PWM, in part due to her escalating flirtation with Celeste. Yasmin and Celeste eventually have sex, but Celeste reveals she is already in an open marriage with her wife and resents the power imbalance in their relationship, making Yasmin realize their affair is not as significant as she imagined. Yasmin brings in her father, Charles Hanani, as a PWM client, but soon regrets it after learning about his various affairs and subsequent NDA settlements, realizing he is a sexual predator. Celeste refuses to cut ties with Charles despite knowing about his inappropriate behavior firsthand, telling Yasmin that it is "better to work within a system and succeed than to wish for it to change and be left behind." A disillusioned Yasmin cuts ties with Celeste shortly thereafter.
Despite the policy of state atheism in East Germany, Christian pastor Christian Führer had regularly met with his congregation at St. Nicholas Church for prayer since 1982. Over the next seven years the church's congregation grew, despite authorities' barricading the adjacent streets, and peaceful candlelit marches took place following its services. The secret police issued death threats and even attacked some of the marchers, but the crowds still continued to gather. On 9 October 1989, the police and army units were given permission to use force against those assembled, but this did not deter the church service and march from taking place, which gathered 70,000 people and in which not a single shot was fired.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.